I assure you the core of this lawsuit will hammer away at Pathway Genomics ethics.
"Giving $10 million in FREE Genetic Testing for women in need" is more low class marketing by Pathway Genomics. This is even worse: "We are a company trying to do good in the world" (horse sh**- Pathway is a company trying for an IPO at any cost)
Why this ranting manager is proud to parade around being sued by Myriad is bizarre, one shouldn't be too cocky about a lawsuit, it's not a positive thing for either party. NO investors will go near Pathway with a law suit like this it puts Pathway in a "risk" category to investors. That IPO that Todd always dreamed of is farther and farther out of reach.
Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status
SAN DIEGO, CA – June 16, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.
“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO.
Pathway Genomics recently began offering BRCATrueTM, its genetic test to help individuals understand their genetic risk for developing breast, ovarian and other types of cancers. It also launched its BRCA One for OneTM program under which Pathway Genomics will provide millions of dollars of free testing to uninsured women. Additionally, as another step in its fight against breast cancer, Pathway Genomics teamed up with Relativity Media last week to co-host a VIP fundraiser in Los Angeles benefiting Susan G. Komen in support of breast cancer testing and awareness.
“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO. “Given their pattern of filing lawsuits against other companies broadening access to this life-saving technology in clear disregard of the Supreme Court’s decision last year, this lawsuit is not unexpected. We do not infringe on any valid patent claims and are prepared to vigorously defend ourselves.”
BRCATrue is a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.
"Giving $10 million in FREE Genetic Testing for women in need" is more low class marketing by Pathway Genomics. This is even worse: "We are a company trying to do good in the world" (horse sh**- Pathway is a company trying for an IPO at any cost)
Why this ranting manager is proud to parade around being sued by Myriad is bizarre, one shouldn't be too cocky about a lawsuit, it's not a positive thing for either party. NO investors will go near Pathway with a law suit like this it puts Pathway in a "risk" category to investors. That IPO that Todd always dreamed of is farther and farther out of reach.
Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status
SAN DIEGO, CA – June 16, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.
“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO.
Pathway Genomics recently began offering BRCATrueTM, its genetic test to help individuals understand their genetic risk for developing breast, ovarian and other types of cancers. It also launched its BRCA One for OneTM program under which Pathway Genomics will provide millions of dollars of free testing to uninsured women. Additionally, as another step in its fight against breast cancer, Pathway Genomics teamed up with Relativity Media last week to co-host a VIP fundraiser in Los Angeles benefiting Susan G. Komen in support of breast cancer testing and awareness.
“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO. “Given their pattern of filing lawsuits against other companies broadening access to this life-saving technology in clear disregard of the Supreme Court’s decision last year, this lawsuit is not unexpected. We do not infringe on any valid patent claims and are prepared to vigorously defend ourselves.”
BRCATrue is a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.